- Conditions
- High Risk Acute Myeloid Leukemia
- Interventions
- CPX-351, 7+3 (cytarabine and daunorubicin)
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2209–2232
of 22,541
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Infant Development
- Interventions
- Infant Formula
- Other
- Lead sponsor
- Aussie Bubs, Inc.
- Industry
- Eligibility
- 1 Day to 14 Days
- Enrollment
- 518 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Centennial, Colorado • Jacksonville, Florida + 25 more
- Conditions
- Herpes Zoster, Postherpetic Neuralgia
- Interventions
- ARYS-01 (sorivudine) cream 3% or placebo cream, placebo, valaciclovir
- Drug
- Lead sponsor
- aRigen Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 10
- States / cities
- Beverly Hills, California • Encino, California • Vista, California + 5 more
- Conditions
- Ovarian Carcinoma
- Interventions
- Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging
- Procedure · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 35 Years to 50 Years · Female only
- Enrollment
- 1,956 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2047
- U.S. locations
- 620
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 406 more
- Conditions
- HIV Infections, Hepatitis C
- Interventions
- Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- PF-00734200 30 mg QD, PF-00734200 20 mg QD, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Litchfield Park, Arizona + 61 more
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Recurrent Adult Brain Tumor
- Interventions
- erlotinib, temsirolimus, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Francisco, California • Bethesda, Maryland + 5 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Implant Procedure, Conventional Synthetic DMARD, Active stimulation, Non-active stimulation
- Procedure · Drug · Device
- Lead sponsor
- SetPoint Medical Corporation
- Industry
- Eligibility
- 22 Years to 75 Years
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 43
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more
- Conditions
- Asymptomatic Amyloid-positive
- Interventions
- Atabecestat, 5 mg, Atabecestat, 25 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 557 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
- Conditions
- Parkinson Disease
- Interventions
- Spheramine (BAY86-5280), Placebo
- Biological · Procedure
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 7 more
- Conditions
- Covid19
- Interventions
- Apixaban 2.5 MG, Placebo
- Drug
- Lead sponsor
- Thomas L. Ortel
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 121
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 101 more
- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- lufepirsen high dose, Vehicle, lufepirsen low dose
- Drug
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 21
- States / cities
- Dothan, Alabama • Petaluma, California • Torrance, California + 17 more
- Conditions
- Peripheral Arterial Disease
- Interventions
- Orforglipron, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Surprise, Arizona + 30 more
- Conditions
- Hepatitis C
- Interventions
- Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 50
- States / cities
- Montgomery, Alabama • Beverly Hills, California • Coronado, California + 37 more
- Conditions
- Sickle Cell Disease
- Interventions
- Voxelotor, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 14 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 13
- States / cities
- Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 5 more
- Conditions
- Postoperative Pain
- Interventions
- Ultrasound imaging, Peripheral nerve stimulator
- Device
- Lead sponsor
- Halyard Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,821 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 16
- States / cities
- Chandler, Arizona • San Jose, California • Louisville, Colorado + 13 more
- Conditions
- Prosthetic Joint Infection, Vancomycin, Joint Diseases
- Interventions
- Experimental Intraosseous vancomycin 500mg in 250 mL NS, Standard IV administration of vancomycin
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- RAD001, erlotinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 4 more
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- Genetic: AAV5-hRKp.RPGR
- Biological
- Lead sponsor
- MeiraGTx Ocular UK Ltd
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 7 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Olokizumab, Placebo
- Drug
- Lead sponsor
- R-Pharm International, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more
- Conditions
- Bladder Cancer
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 35 more
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- Fludarabine, Obinutuzumab, Bendamustine, Cyclophosphamide
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 18
- States / cities
- Huntsville, Alabama • Duarte, California • La Jolla, California + 15 more
- Conditions
- Urea Cycle Disorders, Inborn
- Interventions
- Sodium Benzoate, Sodium Phenylbutyrate
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Peripheral Neuropathy Due to Chemotherapy
- Interventions
- Goal Attainment Scaling (GAS)
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas